Lisata Therapeutics, Inc. (LSTA)
NASDAQ: LSTA · Real-Time Price · USD
5.01
0.00 (0.00%)
At close: Apr 1, 2026, 4:00 PM EDT
5.01
0.00 (0.00%)
After-hours: Apr 1, 2026, 6:47 PM EDT
Lisata Therapeutics Revenue
In the year 2025, Lisata Therapeutics had annual revenue of $170.00K, down -83.00%. Lisata Therapeutics had revenue of $100.00K in the quarter ending December 31, 2025, a decrease of -90.00%.
Revenue (ttm)
$170.00K
Revenue Growth
-83.00%
P/S Ratio
266.19
Revenue / Employee
$8,095
Employees
21
Market Cap
45.25M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 170.00K | -830.00K | -83.00% |
| Dec 31, 2024 | 1.00M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | 22.49M | 4.55M | 25.36% |
| Dec 31, 2014 | 17.94M | 3.27M | 22.30% |
| Dec 31, 2013 | 14.67M | 338.57K | 2.36% |
| Dec 31, 2012 | 14.33M | 4.28M | 42.58% |
| Dec 31, 2011 | 10.05M | -59.77M | -85.61% |
| Dec 31, 2010 | 69.82M | 58.26M | 503.72% |
| Dec 31, 2009 | 11.57M | 11.48M | 13,743.64% |
| Dec 31, 2008 | 83.54K | -148.12K | -63.94% |
| Dec 31, 2007 | 231.66K | 185.94K | 406.66% |
| Dec 31, 2006 | 45.72K | 10.46K | 29.67% |
| Dec 31, 2005 | 35.26K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| NovaBay Pharmaceuticals | 10.30M |
| Immutep | 5.28M |
| Nutriband | 2.28M |
| Werewolf Therapeutics | 1.14M |
| RenovoRx | 1.12M |
| Rallybio | 858.00K |
LSTA News
- 26 days ago - Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc. - GlobeNewsWire
- 2 months ago - Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide - GlobeNewsWire
- 2 months ago - Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer - GlobeNewsWire
- 5 months ago - Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 5 months ago - Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year' - GlobeNewsWire
- 5 months ago - Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent - GlobeNewsWire
- 5 months ago - Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025 - GlobeNewsWire
- 6 months ago - Lisata Therapeutics to Present at LD Micro Main Event XIX - Newsfile Corp